Role of Mesencephalic Astrocyte-Derived Neurotrophic Factor Levels in Pathogenesis of Non-Alcoholic Fatty Liver
DOI:
https://doi.org/10.22317/imj.v7i3.1252Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is one of the main causes of cirrhosis and hepatocellular carcinoma. Recently, the stress response protein mesencephalon-astrocyte-derived neurotrophic factor (MANF) has been shown to regulate hepatic and systemic metabolic homeostasis.
Objectives: The main purpose of this study is to investigate the relationship between mesencephalon-astrocyte-derived neurotrophic factor levels with other anthropometric indicators, and its function in the pathogenesis of non-alcoholic fatty liver disease.
Materials and Methods: A total of 120 patients with ages ranging between 40 to 73 years were included in this study and their serum samples were collected and kept at -2 °C. The liver function test, lipid profile, and albumin were determined using the automated biochemistry analyzer, while the mesencephalic astrocyte-derived neurotrophic factor biomarker was determined by the ELIZA technique.
Results: Our study showed that MANF levels decrease with age, and decreased MANF levels are associated with inflammatory phenotypes. The mean levels of ALT, ALP, AST, TSB, and the ALT/AST ratio in the non-alcoholic fatty liver patients were significantly higher than that for the non-fatty liver patients. As well, the mean level of MANF in the non-fatty liver patients was 305.25 ± 110.49 mg/dl which was significantly higher in the non-alcoholic fatty liver group (157.52). (p ≤ 0.001)
Conclusion: A novel finding of our study is that the reduction of serum MANF levels is strongly associated with the pathogenesis of non-alcoholic fatty liver disorders and could be used as a potential therapeutic target in the treatment of hepatic disorders.
References
Cotter, T. G. and Rinella, M. (2020). Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology, 158(7) : 1851-1864.
Nasiri-Ansari, N., Androutsakos, T., Flessa, C. M., Kyrou, I., Siasos, G., Randeva, H. S. and Papavassiliou, A. G. (2022). Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells, 11(16), 2511..
Day, C. P., and James, O. F. (1998). Steatohepatitis: a tale of two “hits”?. Gastroenterology, 114(4) : 842-845.
Buzzetti, E., Pinzani, M. and Tsochatzis, E. A. (2016). The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 65(8) : 1038-1048.
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., and Melchionda, N. (1999). Association of nonalcoholic fatty liver disease with insulin resistance. The American Journal of medicine, 107(5) : 450-455.
Wu, H., Li, H., Wen, W., Wang, Y., Xu, H., Xu, M., ... & Luo, J. (2021). MANF protects pancreatic acinar cells against alcohol‐induced endoplasmic reticulum stress and cellular injury. Journal of Hepato‐Biliary‐Pancreatic Sciences, 28(10), 883-892.
Tseng, K. Y., Danilova, T., Domanskyi, A., Saarma, M., Lindahl, M., & Airavaara, M. (2017). MANF is essential for neurite extension and neuronal migration in the developing cortex. eneuro, 4(5).
Sousa-Victor, P., Neves, J., Cedron-Craft, W., Ventura, P. B., Liao, C. Y., Riley, R. R. and Jasper, H. (2019). MANF regulates metabolic and immune homeostasis in aging and protects against liver damage. Nature Metabolism, 1(2) : 276-290.
Mizobuchi, N., Hoseki, J., Kubota, H., Toyokuni, S., Nozaki, J. I., Naitoh, M., ... and Nagata, K. (2007). ARMET is a soluble ER protein induced by the unfolded protein response via ERSE-II element. Cell structure and function, 32(1) : 41-50.
Hellman, M., Arumäe, U., Yu, L. Y., Lindholm, P., Peränen, J., Saarma, M. and Permi, P. (2011). Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons. Journal of biological chemistry, 286(4) : 2675-2680.
Kim, Y., Park, S. J. andChen, Y. M. (2017). Mesencephalic astrocyte-derived neurotrophic factor (MANF), a new player in endoplasmic reticulum diseases: structure, biology, and therapeutic roles. Translational Research, 188 : 1-9.
Wu, T., Liu, Q., Li, Y., Li, H., Chen, L., Yang, X. and He, J. (2021). Feeding-induced hepatokine, Manf, ameliorates diet-induced obesity by promoting adipose browning via p38 MAPK pathway. Journal of Experimental Medicine, 218(6) : e20201203.
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M. and George, J. (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of hepatology, 73(1) : 202-209.
Sousa-Victor, P., Neves, J., Cedron-Craft, W., Ventura, P. B., Liao, C. Y., Riley, R. R. and Jasper, H. (2019). MANF regulates metabolic and immune homeostasis in aging and protects against liver damage. Nature Metabolism, 1(2) : 276-290.
He, M., Wang, C., Long, X. H., Peng, J. J., Liu, D. F., Yang, G. Y. and Zhang, L. L. (2020). Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism. World journal of gastroenterology, 26(10) : 1029.
Cordero-Llana, Ó., Houghton, B. C., Rinaldi, F., Taylor, H., Yáñez-Muñoz, R. J., Uney, J. B. and Caldwell, M. A. (2015). Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease. Molecular Therapy, 23(2) : 244-254..
Ezhilarasan D, Lakshmi T. 2022 A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. Oxid Med Cell Longev. 2022 May 11: 9233650.
Yang, L., Shen, W. W., Shao, W., Zhao, Q., Pang, G. Z., Yang, Y. and Shen, Y. X. (2023). MANF ameliorates DSS-induced mouse colitis via restricting Ly6ChiCX3CR1int macrophage transformation and suppressing CHOP-BATF2 signaling pathway. Acta Pharmacologica Sinica : 1-16.
Donini, L. M., Pinto, A., Giusti, A. M., Lenzi, A. and Poggiogalle, E. (2020). Obesity or BMI paradox? Beneath the tip of the iceberg. Frontiers in Nutrition, 7 : 53.
Schindhelm, R. K., Diamant, M., Dekker, J. M., Tushuizen, M. E., Teerlink, T., & Heine, R. J. (2006). Alanine aminotransferase as a marker of non‐alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes/metabolism research and reviews, 22(6) : 437-443.
Su, W., Mao, Z., Liu, Y., Zhang, X., Zhang, W., Gustafsson, J. A. and Guan, Y. (2019). Role of HSD17B13 in the liver physiology and pathophysiology. Molecular and cellular endocrinology, 489 : 119-125.
Chen, C. B., Hammo, B., Barry, J., & Radhakrishnan, K. (2021). Overview of albumin physiology and its role in pediatric diseases. Current gastroenterology reports, 23(8) : 11.
Sousa-Victor, P., Neves, J., Cedron-Craft, W., Ventura, P. B., Liao, C. Y., Riley, R. R. and Jasper, H. (2019). MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage. Nature metabolism, 1(2) : 276-290.
Yang S., Huang S., Gaertig M. A., Li X. J., Li S. (2014). Age-dependent decrease in chaperone activity impairs MANF expression, leading to Purkinje cell degeneration in inducible SCA17 mice. Neuron, 81: 349–365.
Wu, T., Liu, Q., Li, Y., Li, H., Chen, L., Yang, X. and He, J. (2021). Feeding-induced hepatokine, Manf, ameliorates diet-induced obesity by promoting adipose browning via p38 MAPK pathway. Journal of Experimental Medicine, 218(6) : e20201203.
Tang Q, Li Y, He J. MANF: an emerging therapeutic target for metabolic diseases. Trends Endocrinol Metab. 2022 Apr;33(4):236-246. doi: 10.1016/j.tem.2022.01.001. Epub 2022 Feb 5. PMID: 35135706.
Galli, E., Rossi, J., Neumann, T., Andressoo, J. O., Drinda, S. and Lindholm, P. (2019). Mesencephalic astrocyte-derived neurotrophic factor is upregulated with therapeutic fasting in humans and diet fat withdrawal in obese mice. Scientific reports, 9(1) : 14318.
Adams, L. A., Angulo, P. and Lindor, K. D. (2005). Nonalcoholic fatty liver disease. Cmaj, 172(7) : 899-905.
Xu, K., Zheng, P., Zhao, S., Wang, M., Tu, D., Wei, Q. and Xie, P. (2022). MANF/EWSR1/ANXA6 pathway might as the bridge between hypolipidemia and major depressive disorder. Translational Psychiatry, 12(1), 527.
He, M., Wang, C., Long, X. H., Peng, J. J., Liu, D. F., Yang, G. Y. and Zhang, L. L. (2020). Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism. World journal of gastroenterology, 26(10) : 1029.